إعلان
إعلان
RARE
Ultragenyx Pharmaceutical Inc.
23.61
USDبرعاية
+0.61
+2.63%
٠٢ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
23.55
-0.06
-0.24%
تقارير أرباح RARE
النسبة الإيجابية المفاجئة
RARE تفوق 20 من 40 آخر التقديرات.
50%
التقرير التالي
بيانات التقرير القادم
١١ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$191.52M
/-$1.19
التغير الضمني من Q3 25 (Revenue/ EPS)
+19.75%
/-34.25%
التغير الضمني من Q4 24 (Revenue/ EPS)
+16.16%
/-14.39%
Ultragenyx Pharmaceutical Inc. earnings per share and revenue
On ٠٤ نوفمبر ٢٠٢٥, RARE reported earnings of -1.81 USD per share (EPS) for Q3 25, missing the estimate of -1.25 USD, resulting in a -43.74% surprise. Revenue reached 159.93 مليون, compared to an expected 170.04 مليون, with a -5.95% difference. The market reacted with a -1.82% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 22 analysts forecast an EPS of -1.19 USD, with revenue projected to reach 191.52 مليون USD, implying an decrease of -34.25% EPS, and increase of 19.75% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
١٩ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.25
الفعلي
-$0.19
مفاجئة
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.81, missing estimates by -43.74%, and revenue of $159.93M, -5.95% below expectations.
How did the market react to Ultragenyx Pharmaceutical Inc.'s Q3 2025 earnings?
The stock price moved down -1.82%, changed from $32.46 before the earnings release to $31.87 the day after.
When is Ultragenyx Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for ١١ فبراير ٢٠٢٦.
What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?
Based on 22
analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.19 and revenue of $191.52M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان